Hope Medicine Inc. announced first patient dosing in a Phase III clinical study evaluating HMI-115, its first-in-class monoclonal antibody, for moderate-to-severe endometriosis-associated pain in China – advancing the globally unique non-hormonal therapy that has secured Fast Track Designation (FTD) in the US and Breakthrough Therapy Designation (BTD) in China toward potential regulatory approval.
First-in-class monoclonal antibody with unique mechanism
Market Impact & Outlook
Endometriosis Market Dynamics: Global endometriosis therapeutics US$2-3 billion annually; pain management segment US$1.5-2 billion; non-hormonal therapies represent <5% of market due to lack of approved options; HMI-115’s hormone-sparing profile could capture 30-40% of market (patients seeking fertility preservation or intolerant to hormonal side effects).
China Market Strategy: Phase III China-first development supports CDE BTD pathway; domestic innovation positioning may accelerate NMPA approval (2028-2029); China represents largest endometriosis population globally (~30 million diagnosed cases); pricing flexibility vs. import dependency.
US Regulatory Trajectory: FTD supports rolling NDA submission; Phase III data may enable priority review (6-month FDA timeline); US market entry 2029-2030 assuming positive Phase III; partnership with US commercialization partner likely (Abbott, Myovant, or global pharma).
Global Expansion Potential: EU EMA submission 2028-2029; Japan PMDA 2029-2030; estimated US$1-1.5 billion global peak sales (2032-2035) assuming 25-30% market share in non-hormonal segment; licensing deal potential US$300-500 million upfront for ex-China rights upon Phase III interim data.
Hope Medicine Platform Validation: HMI-115 lead asset validates monoclonal antibody discovery platform; pipeline expansion to other gynecological conditions (uterine fibroids, adenomyosis) using similar mechanism; potential for combination with hormonal therapies for severe disease.
Forward-Looking Statements This brief contains forward-looking statements regarding clinical development timelines, regulatory pathway expectations, and commercial projections for HMI-115. Actual results may differ due to Phase III trial outcomes, competitive dynamics with emerging non-hormonal therapies, and manufacturing scale-up for monoclonal antibody production.-Fineline Info & Tech
